Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention
نویسندگان
چکیده
منابع مشابه
Prevention of shingles: safety and efficacy of live zoster vaccine
Primary infection with varicella zoster virus (VZV) causes chickenpox (varicella) after which virus becomes latent in cranial nerve, dorsal root and autonomic ganglia along the entire neuraxis. Virus may later reactivate, causing shingles (zoster), characterized by pain and rash restricted to 1-3 dermatomes. More than 40% of zoster patients over age 60 develop postherpetic neuralgia (PHN), pain...
متن کاملZoster vaccine live for the prevention of shingles in the elderly patient
Shingles, also known as herpes zoster, is a common disease in the elderly population that is caused by reactivation of latent varicella zoster virus. Its manifestations and complications can lead to significant short- and long-term morbidity. In 2006, the United States Food and Drug Administration approved Zoster Vaccine Live (Zostavax) for the prevention of herpes zoster in immunocompetent adu...
متن کاملSafety of herpes zoster vaccine in the shingles prevention study: a randomized trial.
BACKGROUND The herpes zoster vaccine is effective in preventing herpes zoster and postherpetic neuralgia in immunocompetent older adults. However, its safety has not been described in depth. OBJECTIVE To describe local adverse effects and short- and long-term safety profiles of herpes zoster vaccine in immunocompetent older adults. DESIGN Randomized, placebo-controlled trial with enrollment...
متن کاملAdjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
n engl j med 373;16 nejm.org october 15, 2015 1575 Observations from each trajectory are also interesting (Table 1). An FEV1 that is normal at cohort inception without COPD at the final examination (trajectory 1) seems reasonable. An FEV1 that is normal or low at cohort inception with concomitant COPD at the final examination (trajectories 3 and 4) does also, especially considering the authors’...
متن کاملPersistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy.
BACKGROUND The Shingles Prevention Study (SPS; Department of Veterans Affairs Cooperative Study 403) demonstrated that zoster vaccine was efficacious through 4 years after vaccination. The Short-Term Persistence Substudy (STPS) was initiated after the SPS to further assess the persistence of vaccine efficacy. METHODS The STPS re-enrolled 7320 vaccine and 6950 placebo recipients from the 38 54...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Review of Vaccines
سال: 2018
ISSN: 1476-0584,1744-8395
DOI: 10.1080/14760584.2018.1495565